Table 6.

Association of CYP2D6 metabolizer status (based on genotype and drug inhibitor) with breast cancer risk

TreatmentStatusExtensive (baseline)IntermediatePoorMetabolizer status unknown
TamoxifenControls202295935
Cases111156483
OR10.9570.942
95% CI(0.697–1.315)(0.609–1.458)
P0.7870.789
RaloxifeneControls184250943
Cases83134560
OR11.1961.306
95% CI(0.852–1.679)(0.857–1.992)
P0.30.214
TotalControls3865451878
Cases1942901043
OR11.0641.112
95% CI(0.844–1.341)(0.822–1.505)
P0.5990.491